NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

November 2, 2021

Primary Completion Date

March 14, 2022

Study Completion Date

March 14, 2022

Conditions
Suspected or Confirmed COVID-19
Interventions
DRUG

NBT-NM108

Taken in the form of drinks four times a day (before each main meal and 2 hours after dinner) for 28 days. Each drink is prepared by mixing one sachet (30 g) with 500 ml of water.

OTHER

Usual Care Only

Control group will also follow the same schedule except they will drink the same volume of water without NBT-NM108.

Trial Locations (1)

33612

University of South Florida Morsani College of Medicine, Tampa

All Listed Sponsors
collaborator

University of South Florida

OTHER

collaborator

Rutgers University

OTHER

lead

Notitia Biotechnologies Company

INDUSTRY

NCT04540406 - NBT-NM108 as an Early Treatment for Suspected or Confirmed Symptomatic COVID-19 Patients | Biotech Hunter | Biotech Hunter